Abstract

Owing to their anti-inflammatory properties, leukotriene modifiers have been the primary therapeutics in asthma management for several years. Although blocking the inflammatory component of human disease is a long-standing and established concept, the use of leukotriene modifiers in treating the inflammatory component of cardiovascular disease encompassing atherosclerosis, myocardial infarction, stroke and aortic aneurysm has, surprisingly, only been seriously contemplated in the past few years. As reviewed here, several exciting studies have recently contributed to this expanding area of interest, and so far one leukotriene modifier has entered Phase II clinical trials to assess its potential for reducing the risk of heart attacks.

Author affiliations

1. Departments of Biochemistry and Physiology, Queen's University, Kingston, ON K7L 3N6, Canada
   Email: funkc@post.queensu.ca

Published online 22 July 2005

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.